Biochemical mechanisms of drug action: What does it take for success?

Nature Reviews Drug Discovery

Volumn 3, Issue 9, 2004, Pages 801-808

  Swinney, David C ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE; ACETYLCHOLINESTERASE; ACETYLSALICYLIC ACID; ADENOSINE TRIPHOSPHATASE (POTASSIUM); AMINE OXIDASE (FLAVIN CONTAINING); ANGIOTENSIN 2 RECEPTOR; AROMATASE; BETA LACTAMASE; BICALUTAMIDE; CANDESARTAN HEXETIL; CELECOXIB; CLAVULANIC ACID; CYCLOOXYGENASE 2; DESLORATADINE; FINASTERIDE; FORMESTANE; LANSOPRAZOLE; MUSCARINIC M3 RECEPTOR; OMEPRAZOLE; RIVASTIGMINE; SELEGILINE; STEROID 5ALPHA REDUCTASE; SULBACTAM; TAZOBACTAM; TELMISARTAN; TIOTROPIUM BROMIDE; TRANYLCYPROMINE; UNINDEXED DRUG; VALDECOXIB; VIGABATRIN;

ARTICLE; BINDING AFFINITY; BINDING SITE; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; ENZYME INHIBITION; MOLECULAR MECHANICS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STEADY STATE;

ANIMALS; BINDING, COMPETITIVE; BIOCHEMISTRY; DRUG DESIGN; DRUG THERAPY; ENZYME INHIBITORS; HUMANS; MODELS, BIOLOGICAL; PHARMACOLOGY;

EID: 4544381198     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1500     Document Type: Article

References (64)

1. Hopkins, A. L., & Groom, C. R. The druggable genome. Nature Rev. Drug Discov. 1, 727-730 (2002).
2. 50) or an enzymatic reaction. Biochem. Pharm. 22, 3099-3108 (1973).
3. Westley, A. M. & Westley J. Enzyme inhibition in open systems. Superiority of uncompetitive agents. J. Biol. Chem. 271, 5347-5352 (1996).
4. Roth, G. J. & Majerus, P. W. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J. Clin. Invest. 56, 624-632 (1975).
5. +)-ATPase within the parietal cell. Biochim. Biophys. Acta 778, 549-558 (1984).
6. + ATPase. Annu. Rev. Pharmacol. Toxicol. 35, 277-305 (1995).
7. Brown, R. P., Aplin, R. T. & Schofield, C. J. Inhibition of TEM-2 β-lactamase from Escherichia coli by clavulanic acid: observation of intermediates by electrospray ionization mass spectrometry. Biochemistry 35, 12421-12432 (1996).
8. Therrien, C., Kotra, L. P., Sanschagrin, F., Mobashery, S. & Levesque, R. C. Evaluation of inhibition of the carbenicillin-hydrolyzing β-lactamase PSE-4 by the clinically used mechanism-based inhibitors. FEBS Let. 470, 285-292 (2000).
9. Therapeutic Drugs 2nd edn (ed. Dollery, C.) T16-T20 (Churchill Livingston Edinburgh, 1999).
10. Laux G., Volz, H. P. & Moller, H. J. Newer and older monoamine oxidase inhibitors: a comparative profile. CNS Drugs 3, 145-158 (1995).
11. Angehagen, M., Ben-Menachem, E., Ronnback, L. & Hansson, E. Novel mechanisms of action of three antiepileptic drugs, vigabatrin, tiagabine, and topiramate. Neurochem. Res. 28, 333-340 (2003).
12. Bull, H. G. et al. Mechanism-based inhibition of human steroid 5α-reductase by finasteride: enzyme-catalyzed formation of NADP-dihydrofinasteride, a potent bisubstrate analog inhibitor. J. Am. Chem. Soc. 118, 2359-2365 (1996).
13. Brodie, A. M. H., Wing, L. Y., Goss, P., Dowsett, M. & Coombes, R. C. Aromatase inhibitors and the treatment of breast cancer. J. Steroid Biochem. 24, 91-97 (1986).
14. Walker, M. C. et al. A three-step kinetic mechanism for selective inhibition of cyclooxygenase-2 by diarylheterocyclic inhibitors. Biochem. J. 357, 709-718 (2001)
15. Hood, W. F. et al. Characterization of celecoxib and valdecoxib binding to cyclooxygenase. Mol. Pharmacol. 63, 870-877 (2003).
16. Bar-on, P. et al. Kinetic and structural studies on the interaction of cholinesterase with the anti-Alzheimer drug rivastigmine. Biochemistry 41, 3555-3564 (2002).
17. So, O.-Y., Scarafia, L. S., Mak, A. Y., Callan, O. H. & Swinney, D. C. The dynamics of prostaglandin H syntheses. Studies with prostaglandin H synthase 2 Y355F unmask mechanisms of time-dependent inhibition and allosteric activation. J. Biol. Chem. 273, 5801-5807 (1998).
18. Copeland, R. A. et al. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc. Natl Acad. Sci. USA 91, 11202-11206 (1994).
19. Vauquelin, G., Van Liefde, I., Birzbier, B. B. & Vanderheyden, P. M. L. New insights in insurmountable antagonism. Fundam. Clin. Pharmacol. 16, 263-272 (2002).
20. 3H-candesartan is independent of receptor internalization. Biochem. Pharmacol. 61, 1227-1235 (2001).
21. Maillard, M. P. et al. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J. Pharmacol. Exp. Ther. 302, 1089-1095 (2002).
22. 1 receptor. Euro. J. Pharmacol. 449, 229-237 (2002).
23. Steinmetz, A. C. U., Renaud, J.-P. & Mores, D. Binding of ligands and activation of transcription by nuclear receptors. Annu. Rev. Biophys. Biomol. Struct. 30, 329-359 (2001).
24. Dennis, A. P., Haq, R. U. I. & Nawaz, Z. Importance of the regulation of nuclear receptor degradation. Front. Biosci. 6, 954-959 (2001).
25. Waller, A. S., Sharrard, R. M., Berthon, P. & Maitland, N. J. Androgen receptor localisation and turnover in human prostate epithelium treated with the antiandrogen, casodex. J. Mol. Endocrin. 24, 339-351 (2000).
26. McDonnell, D. P. The molecular pharmacology of SERMs. Trends Endocrin. Metabol. 10, 301-311 (1999).
27. Fagart, J. et al. Antagonism in the human mineralocorticoid receptor. EMBO J. 17, 3317-3325 (1998).
28. Fleckenstein, A. Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Annu. Rev. Pharmacol. Tox. 17, 149-166 (1977).
29. Lee, K. S. & Tsien, R. W. Mechanism of calcium channel blockade by verapamil, D600, diltiazem and nitrendipine in single dialysed heart cells. Nature 302, 790-794 (1983).
30. Johnson, B. D., Hockerman, G. H., Scheuer, T. & Catterall, W. A. Distinct effects of mutations in transmembrane segment IVS6 on block of L-type calcium channels by structurally similar phenylalkylamines. Mol. Pharmacol. 50, 1388-1400 (1996).
31. Catterall, W. A. Molecular properties of brain sodium channels: an important target for anticonvulsant drugs. Adv. Neurol. 79, 441-456 (1999).
32. Kuo, C.-C. & Bean, B. P. Slow binding of phenytoin to inactivated sodium channels in rat hippocampal neurons. Mol. Phalmacol. 46, 716-725 (1994).
33. Lewis, H. D., Davis, J. W. & Archibald, D. G. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. New Eng. J. Med. 309, 396-403 (1983).
34. Blower, P. R. Granisetron: relating pharmacology to clinical efficacy. Support Care Cancer 11, 93-100 (2003).
35. Van Noord, J. A., Smeets, J. J., Custers, F. L. J., Korducki, L. & Cornelissen, P. J. G. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur. Respir. J. 19, 639-644 (2002).
36. 2 receptor explain the action of atypical antipsychotics?: a new hypothesis. Am. J. Psychiatry 158, 360-369 (2001).
37. Rabinowitz, J. D., Beeson, C., Lyons, D. S., Davis, M. M. & McConnell, H. M. Kinetic discrimination in T-cell activation. Proc. Natl. Acad. Sci. USA 93, 1401-1405 (1996).
38. Savage, P. A., Boniface, J. J. & Davis, M. M. A kinetic basis for T-cell receptor repertoire selection during an immune response. Immunity 10, 485-492 (1999).
39. Liu, X. & Bosselut, R. Duration of TCR signaling controls CD4-CD8 lineage differentiation in vivo. Nature Immunol. 5, 280-288 (2004).
40. Bjork, I., Nordling, K., Larsson, I. & Olson, S. T. Kinetic characterization of the substrate reaction between a complex of antithrombin with a synthetic reactive-bond loop tetradecapeptide and four target proteinases of the inhibitor. J. Biol. Chem. 267, 19047-19050 (1992).
41. Stone, S. R. & Hermans, J. M. Inhibitory mechanism of serpins. Interaction of thrombin with antithrombin and protease nexin I. Biochemistry 34, 5164-5172 (1995).
42. Cunningham, E. L., Jaswal, S. S., Sohl, J. L. & Agard, D. A. Kinetic stability as a mechanism for protease longevity. Proc. Natl Acad. Sci. USA 96, 11008-11014 (1999).
43. Rindeau, D. et al. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors using sensitive microsomal and platelet assays. Can. J. Physiol. Pharmacol. 75, 1088-1095 (1997).
44. 3H]candesartan to angiotensin II AT1 receptor-transfected Chinese hamster ovary cells. Eur. J. Pharmacol. 367, 413-422 (1999).
45. 1 receptor antagonists on angiotensin II induced tone in human isolated subcutaneous resistance arteries. Br. J. Pharmacol. 127, 1876-1882 (1999).
46. 1 angiotensin II receptor antagonists. J. Med. Chem. 36, 3371-3380 (1993).
47. 1 subtype angiotensin II receptor antagonist. J. Pharmacol. Exp. Ther. 265, 826-834 (1993).
48. 1-receptor subtype. Br. J. Pharmacol. 110, 761-771 (1993).
49. Wienen, W. et al. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br. J. Pharmacol. 110, 245-252 (1993).
50. Edwards, R. M. et al. Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SF&F 108566. J. Pharmacol. Exp. Ther. 260, 175-181 (1992).
51. Corsini, A., Maggi, F. M. & Catapano, A. L. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharm. Rev. 31, 9-27 (1995).
52. 3H]Ba 679, a slow-dissociating muscarinic receptor antagonist in human lung: radioligand binding and autoradiographic mapping. Mol. Pharmacol. 45, 899-907 (1994).
53. Nilvebrant, L., Hallen, B. & Larsson, G. Tolerodine - a bladder selective muscarinic receptor antagonist: preclinical pharmacology and clinical data. Life Sci. 60, 1129-1136 (1997).
54. 3H]Amlodipine binding to rat cardiac membranes, J. Cardiovasc. Pharmacol. 17, 587-592 (1991).
55. Sun, J. & Triggle, D. J. Calcium channel antagonists: cardiovascular selectivity of action. J. Pharmacol. Exp. Ther. 274, 419-426 (1995).
56. Kemppainen, J. A. et al. Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol. Endocrinol. 13, 440-454 (1999).
57. Kraft, K. S., Ruenitz, P. C. & Bartlett, M. G. Carboxylic acid analogues of tamoxifen: (Z)-2[p-(1,2-diphenyl-a-butenyl)phenoxy]-N,N-dimethylethylamine. Estrogen receptor affinity and estrogen antagonist effects in MCF cells. J. Med. Chem. 42, 3126-3133 (1999).
58. Miller, C. P. et al. Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens. J. Med. Chem. 44, 1654-1657 (2001).
59. Couette, B., Lombes, M., Baulieu, E.-E. & Rafestin-Oblin, M.-E. Aldosterone antagonists destabilize the mineralocorticosteroid receptor. Biochem. J. 282, 697-702 (1992).
60. Massaad, C., Lombes, M., Aggerbeck, M., Rafestin-Oblin, M.-E. & Barouki, R. Cell-specific, promoter-dependent mineralocorticoid agonist activity of spironolactone. Mol. Pharmacol. 51, 285-297 (1996).
61. Edwards, D. E. et al. Progesterone receptor and the mechanism of action of progesterone antagonists. J. Steroid Biochem. Mol. Biol. 53, 449-458 (1995).
62. 14C-glycerol into different species of phosphatidic acid, phosphatidylethanolamine, and phosphatidylcholine. J. Biol. Chem. 243, 4440-4451 (1968).
63. Carter, G. W. et al. 5-Lipoxygenase inhibitory activity of Zileuton. J. Pharmacol. Exp. Ther. 256, 929-937 (1990).
64. Krell, R. D. et al. The preclinical pharmacology of ICI 204,219. A peptide leukotriene antagonist. Am. Rev. Respir. Dis. 141, 978-987 (1990).